Nashville-based eye care pharmaceutical company Harrow Inc. reported mixed results for the third quarter on Monday, with earnings that beat analysts' expectations and revenue that fell short of estimates.

Mark Baum Photo: Hamilton Matthew Masters

Harrow, which also gave an update on its recent agreement to acquire Melt Pharmaceuticals Inc. (read here ), reported Q3 earnings per share of $0.30, $0.09 better than analysts' estimate of $0.24.

Revenue for the quarter came in at $71.6 million, a record for the company in the third quarter but short of the consensus estimate of $73.6 million, according to investing.com The company reported $1.0 million of net income and cash and cash equivalents of $74.3 million as of Sept. 30.

In a letter to shareholders, Harrow CEO Mark Baum said th

See Full Page